Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Trial Profile

A Phase 1/2 Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2019

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CHAMPION-1
  • Sponsors Amgen; Onyx Pharmaceuticals
  • Most Recent Events

    • 04 Jun 2019 Results of post hoc analysis comparing between patients who received Kd56 BIW in the ENDEAVOR trial and patients who received Kd70 QW in the A.R.R.O.W. or CHAMPION-1 trials published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology
    • 04 Dec 2018 Results of combined analysis of Carfilzomib trials (CHAMPION-1 , ARROW and ENDEAVOR) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 29 Nov 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top